Market Cap • Polaryx Therapeutics
PLYX
Polaryx Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for lysosomal storage disorders (LSDs) and other rare, life-threatening diseases. The company's primary focus is on repurposing and optimizing existing compounds to address the unmet medical needs of patients with genetic disorders that affect the central nervous system and other vital organs. Polaryx's lead product candidate, PLX-101, is an oral small molecule being developed for the treatment of Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL), also known as CLN2 disease. PLX-101 works by activating the Peroxisome Proliferator-Activated Receptor alpha (PPARα) and the Transcription Factor EB (TFEB), which are critical regulators of lysosomal biogenesis and autophagy. By enhancing these pathways, the therapy aims to reduce the accumulation of toxic storage material in cells, potentially slowing or halting disease progression. In addition to CLN2, the company is exploring the application of its technology platform across other forms of Neuronal Ceroid Lipofuscinosis (NCL) and various lysosomal storage diseases. Polaryx leverages a strategy of utilizing well-characterized molecules to accelerate clinical development timelines and reduce safety risks. The company is led by a management team with extensive experience in drug development and rare disease research, aiming to provide accessible, non-invasive treatment options for pediatric and adult patients worldwide.
107M
Market Cap
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
103,9M
EV
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
0
EV/Revenue
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
-22
EV/EBITDA
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
-22
EV/EBIT
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!